Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 6/20 | 0.38 |
| ▸ | FNTA | P49354 | 9/20 | 0.33 |
| ▸ | FNTB | P49356 | 7/20 | 0.33 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28690269 | 0.86 | BTN3A1 (0.36) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL2594778 | 0.80 | TSHR (0.32) | — | |
| SCHEMBL23013402 | 0.78 | BTN3A1 (0.43) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL18796260 | 0.78 | BTN3A1 (0.43) | BTN3A1FNTAFNTBPGGT1B | |
| Crotyl Pyrophosphate SCHEMBL2513892 | 0.77 | BTN3A1 (0.60) | BTN3A1FNTAFNTBPGGT1B | |
| Crotyl Pyrophosphate SCHEMBL14993578 | 0.77 | BTN3A1 (0.60) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL1506680 | 0.76 | — | — | |
| SCHEMBL13268920 | 0.76 | — | — | |
| SCHEMBL6537391 | 0.76 | TSHR (0.41) | — | |
| SCHEMBL6537388 | 0.76 | TSHR (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637659-B2 | Expansion of non-haematopoietic tissue-resident gamma delta T cells and uses of these cells | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| EP-4010082-B9 | MULTISPECIFIC ANTI-TCR DELTA VARIABLE 1 ANTIBODIES | GAMMADELTA THERAPEUTICS LTD (GB) | 2026-03-04 | — | — | EP | disclosed |
| US-12458698-B2 | Expansion of γδ T cells, compositions, and methods of use thereof | KING'S COLLEGE LONDON (GB) | 2025-11-04 | — | — | US | disclosed |
| US-12312408-B2 | Multispecific anti-TCR delta variable 1 antibodies | GAMMADELTA THERAPEUTICS LTD (GB) | 2025-05-27 | — | — | US | disclosed |
| US-20240376215-A1 | MULTISPECIFIC ANTI-TCR DELTA VARIABLE 1 ANTIBODIES | GAMMADELTA THERAPEUTICS LTD (GB) | 2024-11-14 | — | — | US | disclosed |
| EP-4265642-B1 | MULTISPECIFIC ANTI-TCR DELTA VARIABLE 1 ANTIBODIES | GAMMADELTA THERAPEUTICS LTD (GB) | 2024-06-26 | — | — | EP | disclosed |
| EP-4269444-B1 | MULTISPECIFIC ANTI-TCR DELTA VARIABLE 1 ANTIBODIES | GAMMADELTA THERAPEUTICS LTD (GB) | 2024-06-26 | — | — | EP | disclosed |
| EP-4265643-B1 | MULTISPECIFIC ANTI-TCR DELTA VARIABLE 1 ANTIBODIES | GAMMADELTA THERAPEUTICS LTD (GB) | 2024-06-26 | — | — | EP | disclosed |
| EP-4269446-B1 | MULTISPECIFIC ANTI-TCR DELTA VARIABLE 1 ANTIBODIES | GAMMADELTA THERAPEUTICS LTD (GB) | 2024-06-26 | — | — | EP | disclosed |
| EP-4269445-B1 | MULTISPECIFIC ANTI-TCR DELTA VARIABLE 1 ANTIBODIES | GAMMADELTA THERAPEUTICS LTD (GB) | 2024-06-26 | — | — | EP | disclosed |
| US-20210087528-A1 | EXPANSION OF GAMMA DELTA T CELLS, COMPOSITIONS, AND METHODS OF USE THEREOF | KING'S COLLEGE LONDON (GB) | 2021-03-25 | — | — | US | disclosed |
| WO-2021032961-A1 | EX VIVO GAMMA DELTA T CELL POPULATIONS | GammaDelta Therapeutics Limited (GB) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021032960-A1 | NOVEL ANTI-TCR DELTA VARIABLE 1 ANTIBODIES | GammaDelta Therapeutics Limited (GB) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021032963-A1 | THERAPEUTIC USES OF ANTI-TCR DELTA VARIABLE 1 ANTIBODIES | GammaDelta Therapeutics Limited (GB) | 2021-02-25 | — | — | WO | disclosed |
| EP-3619298-A2 | EXPANSION OF GAMMA DELTA T CELLS, COMPOSITIONS, AND METHODS OF USE THEREOF | King's College London (GB) | 2020-03-11 | — | — | EP | disclosed |
| WO-2018202808-A9 | EXPANSION OF GAMMA DELTA T CELLS, COMPOSITIONS, AND METHODS OF USE THEREOF | KING'S COLLEGE, LONDON (GB) | 2019-03-07 | — | — | WO | disclosed |
| WO-2018202808-A2 | EXPANSION OF GAMMA DELTA T CELLS, COMPOSITIONS, AND METHODS OF USE THEREOF | KING'S COLLEGE, LONDON (GB) | 2018-11-08 | — | — | WO | disclosed |
| US-20180312808-A1 | EXPANSION OF NON-HAEMATOPOIETIC TISSUE-RESIDENT GAMMA DELTA T CELLS AND USES OF THESE CELLS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-11-01 | — | — | US | disclosed |
| EP-3368658-A1 | EXPANSION OF NON-HAEMATOPOIETIC TISSUE-RESIDENT GAMMA DELTA T CELLS AND USES OF THESE CELLS | Cancer Research Technology Limited (GB) | 2018-09-05 | — | — | EP | disclosed |
| WO-2017072367-A1 | EXPANSION OF NON-HAEMATOPOIETIC TISSUE-RESIDENT γδ T CELLS AND USES OF THESE CELLS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637659-B2 | Expansion of non-haematopoietic tissue-resident gamma delta T cells and uses of these cells | IL15, IL15RA, IL2 | BTN3A1 739/4885FNTA 1798/4885FNTB 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.